Submission & Approval

New Drug Application(NDA)

A formal request to the FDA for approval to market a new pharmaceutical drug in the United States.

Usage Examples

The company submitted an NDA for their novel diabetes treatment.
FDA accepted the NDA for filing and assigned a PDUFA date.
The NDA included data from three pivotal Phase 3 clinical trials.

What is NDA?

A New Drug Application (NDA) is the formal submission a pharmaceutical company makes to the FDA to request approval to market a new drug. The NDA contains all scientific data demonstrating the drug's safety and effectiveness for its proposed use.

The NDA must include complete reports of preclinical and clinical studies, information about the drug's composition and manufacturing, proposed labeling, and patent information. The FDA review process typically takes 10-12 months for standard reviews and 6 months for priority reviews.

NDAs are submitted under Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for drugs with full reports of safety and effectiveness investigations.

Regulatory Context

This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 314, 21 CFR 312.

FDAICHEMA

When This Matters

The company submitted an NDA for their novel diabetes treatment.
FDA accepted the NDA for filing and assigned a PDUFA date.
The NDA included data from three pivotal Phase 3 clinical trials.

Common Mistakes

Treating submission readiness as a formatting-only check without lifecycle validation.
Using outdated guidance references across modules and summaries.
Missing cross-functional review between RA, CMC, and quality before submission.

Related Regulations

21 CFR 31421 CFR 312

Frequently Asked Questions

An NDA is for new drugs requiring full safety and efficacy data, while an ANDA (Abbreviated NDA) is for generic drugs that reference an approved drug and only need to demonstrate bioequivalence.

Standard NDA reviews have a 10-month goal date, while priority reviews have a 6-month goal date under PDUFA timelines.

A 505(b)(2) NDA allows applicants to rely partly on FDA findings for a previously approved drug, reducing the need for original clinical data while still enabling approval of modified versions.